The U.S. Supreme Court on Monday turned away Pfizer Inc.’s bid to revive its plan to cover out-of-pocket expenses of Medicare patients for drugs costing $225,000 a year to treat a rare heart condition after federal officials found that the drugmaker’s arrangement could amount to illegal kickbacks.